Ruti Aga's Six-Year Ban: A Forged Prescription, a Mislabeled Drug, and the Defence She Destroyed Herself

The drug on the prescription was real. The prescription was not. And the "doctor" who wrote it was a member of the athlete's own family — a person with no medical registration, who explained the matter by saying he had used "an old prescription pad from a former workplace." The clinic named on the pad did not exist.

On Thursday the Athletics Integrity Unit issued a statement banning the Ethiopian marathon runner Ruti Aga for six years: two years for the presence of a substance that is not permitted on the day of competition, and four years for the document forged to explain it. The ban is dated from 10 September, the same date her provisional suspension began. The statement carries a day and a date but not a year, a small omission worth remembering as this story is read.

This is not the outcome of a marathon. It is the outcome of a paperwork investigation, and that is exactly why it teaches more than the races we build features around every season.

Context: a three-time Major podium runner, and a race in March

Aga is 32. Her career was built in the generation when Ethiopian women's marathoning became the deepest pipeline in the world. Her personal best is not quoted in the source; what public record puts in the margins is a second place in Berlin in 2026 and a win at the Tokyo Marathon in 2026, which is to say one World Marathon Major title and three second places at Majors in all. Those numbers come from recall outside the statement and I am treating them as margin notes pending independent verification, not as headlines.

What the statement does establish: she won a half marathon in China in March, and the in-competition sample from that race contained methylprednisolone. The mark, the splits, the strength of the field — none of it is disclosed. Any judgment of the performance would therefore be invention. All that follows is that she won it, which implies an elite women's field and a race with testing in place. The in-competition window for a road race opens at 23:59 the day before, which is precisely how an injection given days earlier ends up in a bottle.

Core: the arithmetic, the drug class, and one document that failed three separate checks

The sanction adds up cleanly: two years for the presence violation, four for tampering, six in total. That arithmetic is itself information. Two years is the standard entry point for presence, and it can drop if an athlete establishes no fault or no significant fault. Six suggests the panel did not accept that mitigation — the presence charge stuck and nothing in the surrounding story created room to soften it. Four years is the full standard tariff for tampering, applied without reduction.

Now the part least reported. Methylprednisolone has been described in international coverage as a "prohibited steroid" and as performance-enhancing in WADA's view. That is factually wrong. Methylprednisolone is a glucocorticoid, class S9 on the WADA Prohibited List, not an anabolic steroid under S1. And S9 substances are prohibited in-competition only — by injection, orally or rectally. A therapeutic knee injection administered out of competition is entirely legal. It becomes a violation only when residues are present in-competition.

That distinction is not decorative. It defines the entire defence architecture. If the substance is prohibited only in-competition, the athlete had three concrete routes: prove the route and timing of the injection, document the medical necessity, or apply for a therapeutic use exemption. An athlete with a credentialed team physician stands on at least one of those. Aga stood on none.

The forged prescription was therefore not a small shortcut; it was the destruction of the one defence that could actually have worked. Three independent verification checks failed. The clinic on the pad did not exist. The person who wrote it held no medical registration and was a family member. The "old prescription pad" explanation was disowned outright by the clinic it invoked. One document broken in three places is not carelessness — it is the signature of a setup with no verification system at all.

The mixed zone nobody wanted became the only place I could hear the truth, and here the truth is that the four-year sanction came from an interview rather than a document. The statement attributes the tampering charge to statements made under questioning. A fair question follows, raised without offering an excuse: language and translation conditions in AIU interviews with Ethiopian athletes have been a recurring point of contention. That does not make the statements false. It means a large part of a four-year penalty rests on a process whose recording and translation cannot be audited from outside. I learned to wait in corridors — the story usually walks past at eye level, and below the paperwork.

The root, though, is not the drug. It is the knee. The statement itself cites a knee injury, and that is where the case turns from individual to systemic. Chronic knee pathology is among the most common failure modes in high-volume marathon preparation, and a glucocorticoid injection into the knee is standard sports medicine. The drug was not wrong. The timing, the route and the paper were.

An economic logic attaches here. In Indian athletics the payroll is the plot — a railway or police appointment is the structure beneath a personal best. In East African road running the equivalent is the appearance fee. A 2:18–2:20 marathoner's model is a handful of Majors plus Asian label races in between, and China's half marathon circuit is the thickest part of that model. The incentive to mask injury comes from there, because missing a race costs not only form but income. And the gap that incentive falls into is medical: no credentialed team doctor, no TUE process, and a knee treated by someone the family knows.

This case is worth reading because it shows where the investigative frontier has moved. Detection used to be the centre of AIU work. Documentation is now. The decisive exhibit here was not a urine bottle; it was a prescription pad. Which is why a six-year ban now sits on a substance with no established endurance benefit: two years for something that probably does not help, four for the thing that genuinely does — the lie.

What survives? The statement does not define the scope of disqualification. Under standard practice, the result, prize money and subsequent ranking points from the race at which the sample was collected are affected — that is inference, not a declared fact. Results before March are not automatically annulled absent a finding of earlier use. The 2026 Tokyo title and the three Major second places therefore stay on the record, with a date hanging beside them. That record-keeping is the whole job: remembering those who never reached a podium, and keeping an honest account of those who did and then had something taken away. In 2026, in empty stadiums, I built an episode around P. T. Usha's fourth place at Los Angeles in 2026, missed by one hundredth of a second. It taught me that memory is not a neutral machine — it chooses whose margin gets remembered. Aga's margin is now this piece of paper.

The age arithmetic is blunt. Six years on a 32-year-old means a return at roughly 38. Ethiopian women's marathon depth is such that even a 2:18 performer is not automatically selected; a 38-year-old with a doping record is effectively unselectable. In that one sentence the story leaves sport and becomes administration.

Contrarian: is six years a lesson or a message?

The case will split into two camps, each holding half the truth. One will say the AIU was rigorous, and the fact is that four years for tampering is the Code's standard tariff, nothing exceptional. The other will say the penalty is disproportionate, and that is also true — six years for a substance with no proven endurance benefit, in a sport where far more lucrative advantages are caught far less often.

The uncomfortable part is that the panel did not treat the forgery as evidence of doping intent. Logically, an athlete who could have filed a genuine injection record and instead manufactured a false one is signalling concealment. Yet the presence sanction did not escalate. That paradox suggests the panel treated the forgery as a separate offence rather than as proof. The architecture is probably correct, but it produces a side effect: an athlete who files honestly finds a door open, while one who panics and forges finds a career closed — and that difference is determined less by the athlete's ethics than by the competence of the entourage around her.

And the thing that stings most is the label. International coverage turned this into a steroid case. When the category is wrong, the flavour of the punishment is wrong too. A medical-governance failure, in which an injured runner was never shown the correct route, became a morality tale — and morality tales always find the athlete guilty, because her name is remembered and the name of the person taking her fee is not.

Takeaway

What to watch is clear. A CAS appeal window opens for roughly 21 days from the reasoned decision, and a document-based finding is hard to overturn. More telling is whether the reasoned decision names an agent or management; the statement names only a family member. Most telling is the silence of the Ethiopian federation, which has issued no national-level statement at all.

My question is this. If the system's most reliable catch is a forged piece of paper, then who is keeping the ledger on all the correct injections that never became paperwork — simply because nobody ever showed the athlete how the paperwork is done?